---
title: 'Challenges and controversies in resectable non-small cell lung cancer: a clinician''s
  perspective'
date: '2024-03-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38476749/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240313180711&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: The treatment landscape of resectable early-stage non-small cell lung
  cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant
  systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant
  osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, and neoadjuvant nivolumab
  combined with chemotherapy, and the approval of other agents or new indications
  may follow soon. Despite encouraging results, many unaddressed questions remain.
  Moreover, ...
disable_comments: true
---
The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, and neoadjuvant nivolumab combined with chemotherapy, and the approval of other agents or new indications may follow soon. Despite encouraging results, many unaddressed questions remain. Moreover, ...